Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)

Trial Profile

A Randomized, Double Blind Phase III Study To Evaluate Adjuvant cG250 Treatment Versus Placebo In Patients With Clear Cell RCC And High Risk of Recurrence (ARISER)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2018

At a glance

  • Drugs Girentuximab (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ARISER
  • Sponsors Heidelberg Pharma AG
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG
    • 01 Feb 2014 Results of an analysis that investigated the effects of obesity of treatment outcomes presented at the 2014 Genitourinary Cancers Symposium.
    • 05 Jun 2013 Primary endpoint 'Overall-survival' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top